A Review of Olanzapine in the Treatment of Cancer Anorexia-Cachexia Syndrome.
Ivy Oiyee PoonVeronica AjewoleUrsula K BraunPublished in: Pharmacy (Basel, Switzerland) (2024)
Low dose olanzapine (2.5-5 mg once daily) may be useful in the treatment of CAS for increasing appetite, reducing nausea and vomiting, and promoting weight gain. Further large-scale multi-center randomized placebo-controlled studies will be needed to investigate the impact of olanzapine on weight change in CAS patients.
Keyphrases
- weight gain
- low dose
- placebo controlled
- body mass index
- double blind
- weight loss
- crispr cas
- physical activity
- end stage renal disease
- genome editing
- newly diagnosed
- ejection fraction
- squamous cell carcinoma
- birth weight
- clinical trial
- phase ii
- high dose
- radiation therapy
- patient reported outcomes
- peritoneal dialysis
- chemotherapy induced
- body weight
- smoking cessation